Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET DAPT: 3 vs 12 Months DAPT after Firehawk Stent
NCT03008083Phase 4Unknown
- Sponsor
- MicroPort
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of clopidogrel, ticagrelor in coronary artery disease (CAD), sponsored by MicroPort. Status: unknown.
02
Drugs
clopidogrelticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03008083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008083.